Thus, although the marked decrease in E-cadherin levels upon CdGAP downregulation contrasts with the findings in breast cancer, the regulation of other genes hints at a differential mechanism of action of CdGAP in prostate cancer. This evidence concerns the gene ARHGAP31 and breast carcinoma.